Premium
GM‐CSF plays a key role in zymosan‐stimulated human dendritic cells for activation of Th1 and Th17 cells
Author(s) -
Wei WenChi,
Su YiHsuan,
Staniforth Vanisree,
Sheu JyhHorng,
Yang NingSun
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.528.5
Subject(s) - zymosan , microbiology and biotechnology , monocyte , chemistry , t cell , immune system , biology , immunology , biochemistry , in vitro
In this study, we evaluate comparatively the effect of zymosan and LPS on human monocyte‐derived dendritic cells (hDCs). The specific and differential effects of zymosan on the expression of several key cytokines, including granulocyte‐macrophage colony stimulating factor (GM‐CSF), interleukins (IL‐1£\, IL‐1£] and IL‐10) and monocyte chemoattractant protein‐1 (MCP‐1), were found to be distinctive from the effects of LPS. Unlike with LPS activation, DCs under zymosan activation expressed little or no IL‐12 p70 due to the lack of expression of the p35 subunit. However, treatment with zymosan resulted in a substantial increase in Th1 and Th17 cell polarizing capacities. Furthermore, GM‐CSF secreted by zymosan activated DCs enhanced IL‐23 production, subsequently resulting in activation of Th17 response. GM‐CSF and IL‐27, rather than IL‐12 p70, were both major direct contributors to the activation of Th1 response. This mechanism is drastically different or even opposite, but complementary, to the LPS‐mediated T‐cell activation. Therefore, we suggest that this novel, zymosan‐induced, GM‐CSF‐mediated signaling network may be employed as a future guide for modulation and differentiation of specific immune cell type activities.